Skip to search formSkip to main contentSkip to account menu

Brivaracetam

Known as: (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide, 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)-, 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Brivaracetam is currently indicated as adjunctive therapy for patients with focal-onset seizures with or without secondary… 
2017
2017
Objectives To assess state and trait anger, adjusted by epilepsy type, seizure control, anxiety-depression status and quality of… 
Review
2017
Review
2017
Commentary Brivaracetam (BRV) is the latest antiepileptic drug to reach the marketplace, and many clinicians are contemplating… 
Review
2016
Review
2016
Brivaracetam (BRV) is a novel antiepileptic drug recently licensed for the treatment of partial epilepsy in adults and… 
Review
2014
Review
2014
Brivaracetam (BRV) is a new antiepileptic drug structurally related to levetiracetam but with a 15 to 30-fold increased affinity… 
2014
2014
Commentary Despite the availability of multiple AEDs, many patients with epilepsy continue to have refractory seizures as well as… 
Review
2006
Review
2006
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… 
2005
2005
Historically, most antiepileptic drugs (AEDs) have been discovered either by serendipity, or the screening of compounds using…